Comparisons of Staphylococcus aureus infection and other outcomes between users of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers: lessons for COVID-19 from a nationwide cohort study. by Bidulka, Patrick et al.
 Open Peer Review
Any reports and responses or comments on the
article can be found at the end of the article.
RESEARCH ARTICLE
Comparisons of  infection and otherStaphylococcus aureus
outcomes between users of angiotensin-converting-enzyme
inhibitors and angiotensin II receptor blockers: lessons for
 COVID-19 from a nationwide cohort study [version 1; peer
review: 2 approved]
Patrick Bidulka ,       Masao Iwagami , Kathryn E. Mansfield , Fotini Kalogirou ,
       Angel Y. S. Wong , Ian J. Douglas , Liam Smeeth , Charlotte Summers ,
Laurie A. Tomlinson 1
Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
Department of Health Services Research, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK
 Equal contributors
Abstract
 Mice receiving angiotensin converting enzyme inhibitorBackground:
(ACEI) drugs show increased susceptibility to infection by Staphylococcus
( ). We sought to investigate whether humans using ACEIaureus S. aureus
were at increased risk of  infection, comparing them to users of S. aureus
Angiotensin II Receptor Blockers (ARB) with multiple control outcomes to
assess the potential for residual confounding.
 Using the UK Clinical Practice Research Datalink linked toMethods:
Hospital Episode Statistics between 1997 and 2017, we identified adults
starting ACEI or ARB (as an active comparator drug). We regarded
prescription of ACEI or ARB as time-dependent exposure and used a Cox
regression model to compare incidence of first hospitalisation with infection
due to   in periods with ACEI to periods with ARB prescriptions.S. aureus
We repeated the analysis using control outcomes that we did not expect to
be associated with use of ACEI versus ARB (Gram-negative sepsis, hip
fracture and herpes zoster) and one that we did (dry cough).
 We identified 445,341 new users of ACEI (mean age 64.0±14.0,Results:
male 51.7%) and 41,824 new users of ARB (mean age 64.1±14.0, male
45.5%). The fully adjusted hazard ratio for   infection (ACEI vs.S. aureus
ARB) was 1.18 (95% CI 1.10–1.27), consistent across sensitivity analyses.
However, we also found associations with all control outcomes; rates of
Gram-negative sepsis, hip fracture and dry cough were also increased
during periods of time treated with ACEI compared to ARB while herpes
zoster was more common during time treated with ARB.
 Our results suggest that although ARB users appear an idealConclusions:
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  Our results suggest that although ARB users appear an idealConclusions:
control for analyses of ACEI effects, there is residual confounding even
after multivariable adjustment. This has implications for observational
analyses comparing users of these drug classes, in particular the effect of
these drugs in relation to COVID-19 infection.
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Introduction
Angiotensin converting enzyme inhibitor (ACEI) drugs and angi-
otensin II receptor blockers (ARB) are commonly used drugs 
for the treatment of hypertension, proteinuric kidney diseases 
and heart failure1–4. The drugs block activation of different parts 
of the renin-angiotensin system, a hormone system that regu-
lates fluid and electrolyte balance, and blood pressure5. Despite 
their similar clinical uses, the separate mechanisms of action of 
the drug classes means that they may result in different effects 
on other biological systems. For example, in animal mod-
els, angiotensin converting enzyme (ACE) has a role in neu-
trophil antibacterial defences and this effect is independent of 
the angiotensin II receptor where ARB drugs act. Treatment of 
mice with ACEI leads to increased susceptibility to infection 
with Staphylococcus aureus (S. aureus)6. These findings sug-
gest that humans taking ACEI could be at increased risk of 
S. aureus infection compared to users of ARB, but this result 
has not been examined in clinical studies.
The similar indications for ACEI and ARB mean that they 
could be ideal comparator groups in observational analyses of 
drug effects, reducing the potential confounding that can occur 
when comparing drug classes which are prescribed for differ-
ent indications. Users of ACEI have been compared to ARB 
users in a number of important epidemiological studies, some of 
which have proposed a causal association between ACEI use 
and adverse outcomes7–10. Using anonymised primary health 
care records, we sought to compare rates of S. aureus infection 
between users of ACEI and ARB, including Gram-negative infec-
tions as a predefined negative control where we did not expect 
to see an association based on previous research in animals.
During this analysis, the pandemic of coronavirus disease 2019 
(COVID-19) due to the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) began. SARS-CoV-2 uses the 
ACE2 protein, a counter-regulatory component of the renin- 
angiotensin system, to enter alveolar epithelial cells in the 
lungs11. Early reports suggested that people with hypertension, 
chronic kidney disease, cardiovascular disease, and diabetes 
were at higher risk for severe outcomes from COVID-19 than 
people without these comorbidities12. It has been proposed that 
use of drugs affecting the renin-angiotensin system could explain 
this increased risk via effects on the ACE2 enzyme13. However, 
evidence for a possible benefit from these drugs is sufficiently 
strong that a clinical trial has been initiated using an ARB, 
Losartan, as a treatment for COVID-1914.
Given the intense interest in this topic, it is likely that analy-
ses of COVID-19 outcomes in relation to use of ACEI and 
ARB will be repeatedly investigated. We have previously dis-
cussed the epidemiological difficulty of comparing users of 
these drugs to non-users15. Given the interest in potential dif-
ferential effects of ACEI and ARB use in relation to COVID-19, 
we sought to investigate the possibility of residual confounding 
between users of these drug classes using a large, high-quality 
data source where multiple sensitivity analyses can be under-
taken. Therefore, in addition to our original research question, we 
undertook analyses of further outcomes to explore the potential 
limitations of analyses between these two drug classes to 
inform future work regarding COVID-19.
Methods
Data source
The Clinical Practice Research Datalink (CPRD) is an observa-
tional data and interventional research service provided by the 
National Health Service (NHS). Nearly 700 general practices 
have contributed data meeting quality control standards to CPRD, 
representing nearly 7% of the UK population16. The database 
includes the following data: patient demographics; coded diag-
noses (Read codes); prescriptions; laboratory test results; and 
referrals recorded by general practitioners (GPs). In addition, the 
CPRD is linked to inpatient Hospital Episode Statistics (HES) 
in around 400 general practices, accounting for 75% of general 
practices in CPRD in England. HES contains details of all admis-
sions to NHS hospitals in England since 199717, and consists of 
primary and subsidiary diagnoses recorded during admission 
using the 10th revision of International Classification of Dis-
ease (ICD-10) codes18. This study was approved by the LSHTM 
Research Ethics Committee (reference 6536) and the Independ-
ent Scientific Advisory Committee, which oversees research 
involving CPRD data (Protocol 18_021R). Informed consent was 
not required because data are anonymised for research purposes.
Study population
We identified new users of ACEI or ARB (i.e. those without 
any previous prescriptions in the database), aged ≥18 years 
and registered in HES-linked CPRD for ≥1 year, between 
April 1997 and March 2017. We excluded people starting ACEI 
and ARB on the same day. Once individuals were included 
into the study cohort, they were followed up until the first inci-
dence of an outcome or the end of CPRD eligibility, including 
death, change of general practice, last data collection from the 
general practice, or 31st March 2017 (whichever occurred first).
Exposure definition
We considered prescription of ACEI or ARB as time-dependent 
exposure. Supplementary Figure 1 (Extended data19) is a graphi-
cal representation of exposure definition. First, we identified 
periods with ACEI and ARB prescription separately in individu-
als. The duration of each prescription was estimated by divid-
ing the total number of tablets prescribed by the number of 
tablets to be taken each day (daily dose). When the daily dose 
or total number of tablets was missing (around 8.7% of the 
records), we imputed the median prescription duration (28 days). 
We assumed that people were continuously exposed to ACEI 
or ARB if there were no gaps of more than 60 days between 
the end of one prescription and the start of the next (to allow 
potential medication stockpiling or prescribing in secondary 
care). If there was no subsequent prescription of ACEI or ARB, 
we considered people could be influenced by the effect of the 
drug until 60 days after the end of the prescription. Thus, each 
episode of ACEI or ARB treatment started at the first prescrip-
tion (as a new treatment episode) and continued until 60 days 
after a break in continuous prescribing of 60 days (or more). 
An individual could contribute multiple episodes of ACEI or 
ARB treatment during follow-up. Next, we classified individual 
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participants’ follow-up time into: “period with ACEI only,” 
“period with ARB only,” “period with both ACEI and ARB,” 
and “period without ACEI or ARB” (Supplementary Figure 1, 
Extended data19). In the main analysis, we compared “period with 
ACEI only” and “period with ARB only.”
Outcome definition
The primary outcome of interest was S. aureus infection identi-
fied during hospital admissions (HES) and recorded as ICD-10 
codes A41.0 (Sepsis due to Staphylococcus aureus) and B95.6 
(Staphylococcus aureus as the cause of diseases classified to other 
chapters). We did not include outpatient diagnoses of S. aureus 
infection in the CPRD, because this could represent results of 
microbiological swabs not associated with clinically significant 
infection. In the main analysis, we defined the primary outcome 
using the codes of interest in any episode (a single period of care 
under one consultant team) within a spell (a patient’s entire stay 
in hospital) in any diagnostic position in HES (up to 20 diagnoses 
are recorded in order of priority for each episode of care).
In addition to the primary outcome, we included a number of 
negative control outcomes, where we did not expect to see an 
increased risk associated with either ACEI or ARB use. For these 
outcomes, any difference in risk between the groups is there-
fore likely to indicate unadjusted confounding. The first was 
pre-specified, Gram-negative sepsis (defined using ICD-10 
code A41.5 in any diagnostic position in HES in any episode of 
any spell). Post-hoc, after the outbreak of COVID-19, we added 
additional outcomes to further explore potential residual con-
founding. Therefore, we also compared risk of hip fracture 
(defined using ICD-10 code S72 in any diagnostic position in 
HES in any episode of any spell), and the risk of development 
of herpes zoster infection (defined using both primary care 
Read codes and ICD-10 code B02 in HES in any diagnostic 
position in HES in any episode in any spell). Finally, to ensure 
the robustness of our comparisons we added dry cough 
(defined using primary care Read codes) as a positive control 
outcome, where we expected to see an association with ACEI 
use. All outcome and covariate codes used in primary care 
records are available for as Underlying data20.
Covariate definitions
Our covariates were defined a priori, based on knowledge of clini-
cal factors that might influence choice of prescription of ACEI 
or ARB. In the main analyses, in addition to age (<55, 55–64, 
65–74, 75–84, and ≥85 years), sex, and calendar period (1997–
2001, 2002–2006, 2007–2011, and 2012–2016), we considered 
kidney function and comorbidity diagnoses of hypertension1, 
heart failure2, diabetes3, proteinuria3, myocardial infarction4 
and renal replacement therapy (RRT) as time-updated con-
founding factors in the association between ACEI (vs ARB) and 
infection due to S. aureus. We determined kidney function by 
calculating estimated glomerular filtration rate (eGFR) from 
serum creatinine records in the CPRD using the Chronic Kidney 
Disease Epidemiology Collaboration equation21, and categorized 
this as eGFR ≥60, 45–59, 30–44, and <30 mL/min/1.73m2. We 
used a last-carried-forward method22, meaning that eGFR was 
initially defined using the serum creatinine result that marked 
entry to the study and updated at each subsequent creatinine 
result, so that eGFR was always defined by the single most 
recent creatinine result. In the main analysis we grouped indi-
viduals without any serum creatinine measurement prior to the 
cohort entry into the eGFR ≥60 mL/min/1.73m2 category23.
Statistical analysis
We first compared individual characteristics (age category, sex, 
calendar period, kidney function category, and diagnoses of 
hypertension, heart failure, diabetes, proteinuria, myocardial inf-
arction, and RRT) between new users of ACEI and ARB, using 
chi-square tests. Because a proportion of new users of ACEI 
and ARB switched to the other drug during follow-up, we also 
determined time-updated characteristics defined by periods pre-
scribed ACEI or ARB in which the numerator was the length 
of time with each covariate status (e.g. coded as diabetic) 
and the denominator was the total length of ACEI and ARB 
prescription in the study population.
We estimated the crude rate of the first incidence of the out-
come (i.e. hospitalisation with infection due to S. aureus) after 
cohort-entry in periods with and without ACEI and ARB pre-
scription. We used multivariable time-dependent Cox regres-
sion analysis to estimate hazard ratios for the first incidence 
of each outcome, comparing periods of ACEI and ARB use and 
adjusting for the pre-specified, time-updated confounding fac-
tors. All statistical analyses were conducted using Stata 15 
software (Stata Corp, Texas).
Sensitivity and subgroup analyses
For the primary analysis only, to test the robustness of our find-
ings for the definitions used we undertook a number of sensitiv-
ity analyses. First, we included “period with both ACEI and 
ARB” into “period with ACEI only.” Secondly, we examined 
our definition of ACEI and ARB exposure by changing the 60-
day duration of periods between prescriptions, and washout 
periods to 30 and 90 days. Thirdly, we conducted an analy-
sis including multiple covariates related to risk of infection 
which we did not include in the main analysis as we did not 
anticipate they would influence the choice of ACEI or ARB and 
therefore be true confounders: diagnoses of cancer, rheuma-
toid arthritis, systematic lupus erythematosus, inflammatory 
bowel disease, chronic liver disease, chronic pulmonary disease, 
human immunodeficiency virus infection and acquired immune 
deficiency syndrome. We also included prescription of other 
antihypertensives (beta blockers, calcium channel blockers, 
and diuretics), statins, oral corticosteroids, and life-style fac-
tors (smoking status, alcohol status and body mass index). Con-
ditions were considered present if recorded in CPRD prior 
to cohort entry and medications were included if prescribed 
in the year prior to cohort entry. Information on life-style fac-
tors was based on that recorded at the closest time point to the 
cohort entry and not time-updated. Fourth, we repeated the main 
analysis excluding individuals with no serum creatinine meas-
urements recorded prior to the cohort entry. Finally, we exam-
ined our outcome definitions in several ways. We defined the 
outcome using the ICD-10 codes of interest recorded only dur-
ing the first episode of a spell, which are more likely to suggest 
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community-acquired S. aureus infection. We then repeated the 
main analysis including additional non-specific ICD-10 codes 
indicating Staphylococcal infection, including A49.0 (Staphylo-
coccal infection, unspecified site), G00.3 (Staphylococcal men-
ingitis), J15.2 (Pneumonia due to Staphylococcus), and M00.0 
(Staphylococcal arthritis and polyarthritis). Finally, we included 
as our outcome only the severest form of S. aureus infection, 
based on ICD-10 code A41.0 (Sepsis due to Staphylococcus 
aureus).
We also conducted pre-planned subgroup analyses to investi-
gate potential approaches to mitigating residual confounding. To 
examine whether the findings were affected by changes in the 
recording of S. aureus codes over time, we estimated the 
adjusted hazard ratio separately by category of calendar year 
(1997–2001, 2002–2006, 2007–2011, and 2012–2016). Finally, 
we stratified results by previous smoking status to explore 
whether categorisation of ex-smokers as non-smokers in the 
GP record was a potential source of information bias.
Results
We identified 487,326 new users of ACEI or ARB (aged 
≥18 years) registered in HES-linked CPRD for ≥1 year between 
April 1997 and March 2017 (Figure 1). After excluding 161 
individuals prescribed ACEI and ARB simultaneously, there were 
487,165 eligible individuals, including 445,341 new users of 
ACEI (mean age 64.0±14.0, male 51.7%) and 41,824 new users 
of ARBs (mean age 64.1±14.0, male 45.5%). At cohort 
entry, new users of ACEI were more likely to have diabetes, 
myocardial infarction, heart failure, and proteinuria, whereas new 
users of ARB were more likely to have hypertension (Table 1).
During follow-up, 98,461 (22.1 % of 445,341) of new users 
of ACEI switched to ARB, and 9,041 (21.6 % of 41,824) of 
new users of ARB switched to ACEI (Figure 1). Consequently, 
there were 1,759,917 person-years of ACEI prescriptions, and 
644,953 and person-years of ARB prescriptions. The patterns of 
participant characteristics between periods of ACEI and ARB 
prescriptions during follow-up were similar to, but generally 
smaller than, the differences between new users of ACEI and 
ARB at cohort entry (Supplementary Table 1, Extended data19).
In the primary analysis, there were 3,430 and 1,007 first hospi-
talisations with infection due to S. aureus in periods with ACEI 
and ARB, providing the crude incidence rates/1000 person years 
(95% CI) of 1.95 (1.88 – 2.02) and 1.56 (1.47 – 1.66), respectively 
(Table 2).
In the main analysis, the adjusted hazard ratio (HR) for the first 
hospitalisations with infection due to S. aureus comparing periods 
with ACEI vs ARB prescription was 1.18 (95% CI 1.10 – 1.27) 
(Table 2; Figure 2). For the control analyses, we also found an 
association between ACEI prescription and sepsis due to Gram-
negative organisms (adjusted HR 1.16, 95% CI 1.02 – 1.32), 
hip fracture (adjusted HR 1.31, 95% CI 1.25 – 1.38) and dry cough 
(adjusted HR 1.59, 95% CI 1.51 – 1.68) while risk of herpes 
zoster was lower among users of ACEI (adjusted HR 0.91, 95% 
CI 0.88 – 0.94).
Sensitivity analyses showed similar results (Figure 2; Supplemen-
tary Table 2, Extended data19), except that the strength of asso-
ciation between ACEI and sepsis due to S. aureus was smaller 
(adjusted HR 1.09, 95% CI 0.89 – 1.35). In subgroup analy-
ses, there were no clear differences in the adjusted hazard ratio 
(HR) for rates of S. aureus infection by year and smoking status 
(Supplementary Table 3, Extended data19).
Discussion
Our study demonstrated that rates of S. aureus infection are 
higher among users of ACEI than users of ARBs, consistent 
with the hypothesis from animal models we sought to examine6. 
However, our pre-planned control analysis where we did not 
expect to see an association, rates of Gram-negative sepsis, was 
also more common in ACEI users. This could suggest that tak-
ing ACEI leads to an increased susceptibility to infection by both 
types of organism, or that the association with drug class is due 
to underlying differences between users of ACEI and ARB that 
remained despite adjustment for potential confounders.
The importance of this question given the potential role of 
ACEI and ARB drugs in leading to severe outcomes in peo-
ple with COVID-19 infection led to us undertaking post-hoc 
control analyses to explore further the possibility of residual 
confounding. For these analyses we did not expect choice of 
ACEI or ARB to be causally associated with the outcome but 
found that rates of hip fracture were higher in people taking 
ACEI, while herpes zoster infection was higher among those 
Figure 1. Flowchart diagram of identification of participants in 
the study cohort.
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Table 1. Characteristics of the study participants at cohort entry.
New users of ACEIs 
N = 445,341 
n (%)
New users of ARBs 
N = 41,824 
n (%)
Age category (years)
  <55 122,148 (27.4) 10,889 (26.0)
  55–64 106,125 (23.8) 10,061 (24.1)
  65–74 109,317 (24.6) 10,860 (26.0)
  75–84 82,473 (18.5) 7,931 (19.0)
  ≥85 25,278 (5.7) 2,083 (5.0)
Sex
  Women 215,043 (48.3) 22,779 (54.5)
Year
  1997–2001 73,702 (16.6) 7,159 (17.1)
  2002–2006 168,105 (37.8) 22,430 (53.6)
  2007–2011 138,439 (31.1) 7,321 (17.5)
  2012–2016 65,095 (14.6) 4,914 (11.8)
Hypertension 297,625 (66.8) 31,240 (74.7)
Diabetes 75,762 (17.0) 4,634 (11.1)
Myocardial infarction 40,233 (9.0) 1,621 (3.9)
Heart failure 23,243 (5.2) 1,061 (2.5)
Proteinuria diagnosis 5,925 (1.3) 336 (0.8)
Kidney function:
  Not measured 82,755 (18.6) 10,342 (24.7)
  eGFR ≥60 mL/min/1.73m2 291,925 (65.6) 24,447 (58.5)
  eGFR 45-59 mL/min/1.73m2 51,939 (11.7) 5,037 (12.0)
  eGFR 30-44 mL/min/1.73m2 15,254 (3.4) 1,432 (3.4)
  eGFR <30 mL/min/1.73m2 2,828 (0.6) 396 (1.0)
  On renal replacement therapy 640 (0.1) 170 (0.4)
ACEI = angiotensin-converting-enzyme inhibitor, ARB = angiotensin II receptor antagonist, 
eGFR = estimated glomerular filtration rate.
taking ARBs. The positive control, rate of dry cough, was 
substantially higher among ACEI users as we expected, demon-
strating that our approach was able to detect known drug effects. 
Overall, the additional analyses suggest that the associations 
of ACEI use with S. aureus and Gram-negative sepsis is due to 
confounding rather than the drugs causing susceptibility to 
infection.
Comparison of the unadjusted and adjusted hazard ratios for 
analyses of S. aureus and Gram-negative sepsis, shows that the 
adjusted results move towards the null. This suggests that some 
of the increased rate of infections in ACEI users is due to fac-
tors that are associated with drug prescription such as preva-
lence of diabetes and sex, and taking this into account reduces 
the difference in rates between the drug classes. In this analysis 
we had pre-selected covariates with the aim of trying to cap-
ture confounding as well as possible given the data source. 
However, even adjustment for multiple other potential confound-
ers in our sensitivity analysis did not reduce the hazard ratio 
substantially closer to the null.
By contrast with our other analyses, rates of herpes zoster infec-
tion were higher in ARB users. Confounder adjustment moved 
the hazard ratio closer to the null but residual confounding 
remained. This may be because strong risk factors for infec-
tion such as conditions associated with immunosuppression were 
not included in our analysis, as well as family history which is 
hard to define in routine data sources24. Hip fracture was more 
common in ACEI users but confounder adjustment moved 
the hazard ratio away from the null suggesting negative 
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confounding. This may be because women were more likely 
to be prescribed ARBs, and female sex is a major risk factor for 
hip fracture25.
The pre-planned sensitivity analyses altering our definition of 
drug exposure, covariate adjustment or outcome all showed results 
very similar to the main analysis suggesting that the changes 
did not substantially affect residual confounding. We under-
took pre-planned stratified analyses to explore potential sources 
of confounding. We examined the association within shorter 
time intervals over the study period which demonstrated con-
sistent results over the last 15 years, suggesting that focus 
on detection of Staphylococcal infection related to efforts to 
reduce rates of methicillin-resistant S. aureus (MRSA) did not 
impact our results26. Similarly, we considered misclassifica-
tion of ex-smokers as non-smokers to be a potential source of 
information bias potentially contributing to undetected poorer 
health status among users of ACEI in the analysis and partly 
explaining our results. Interestingly, in stratified analyses the 
highest adjusted HR was seen among non-smokers suggesting 
that this consideration should be explored further, but confidence 
intervals overlapped so this result should be interpreted with 
caution.
We have used time-updated drug exposure which is vital for 
exploring causal relationships since we show that approximately 
20% of initiators in each class switch from ACEI to ARB or vice 
versa and thus in a cohort study would be misclassified based 
on baseline drug use. In addition, our primary analysis com-
pares outcomes during time exposed to ACEI to that exposed to 
ARB. However, to highlight the implications of study design 
for future COVID-19 related studies, we chose to present the 
rates of outcomes during time exposed to neither drug (Table 2). 
These results show that risk of all outcomes except herpes zoster 
is markedly greater during this ‘unexposed’ time. We propose that 
this is because the drugs are stopped during periods of illness or 
increasing frailty, and hence unexposed time after drug initia-
tion is associated with a greater risk of adverse outcomes. Inclu-
sion of these time periods in analyses based on baseline drug 
exposure may lead to inappropriate conclusions.
Figure 2. Forest plot of fully adjusted hazard ratios for the outcomes for all analyses, comparing rates during periods of ACEI and 
ARB prescription. *Adjusted  for age (<55, 55–64, 65–74, 75–84, and ≥85 years), sex, year  (1997–2001, 2002–2006, 2007–2011, 2012–
2016),  kidney  function  (eGFR ≥60 mL/min/1.73m2 or  unmeasured,  eGFR 45–59 mL/min/1.73m2,  eGFR 30–44 mL/min/1.73m2,  eGFR <30 
mL/min/1.73m2, or renal replacement therapy), diagnoses of hypertension, diabetes, myocardial infarction, heart failure, and proteinuria: all 
covariates were time-updated.
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There are a number of strengths in our analysis. We have conducted 
a large cohort study using a data source with detailed informa-
tion on confounders and linkage to hospital admission data. We 
have used a range of control and stratified analyses to explore the 
possibility and sources of residual confounding. However, we 
have adjusted for the same covariates for all analyses while the 
underlying confounding structure may be different. Nonetheless, 
adjustment for additional covariates in our sensitivity analy-
ses made no important difference to the main analysis. Addi-
tional adjustment using techniques such as high-dimensional 
propensity scores may reduce confounding compared to stand-
ard multivariable regression27. There is limited validation of the 
codes used to define outcomes in these analyses, but there is no 
reason to think their recording would differ by ACEI or ARB 
use.
A number of influential population-based epidemiological analy-
ses have compared outcomes between ACEI and ARB users7–10. 
Some of these have used considerations such as stratified analy-
sis by cumulative duration of drug use, and by time since 
initiation to examine outcomes including dementia and cancer, 
concluding that associations are unlikely to be causal8,9. How-
ever, these approaches are less relevant to acute outcomes, such 
as infection risks, which can occur at any stage in treatment.
ACEI and ARB drugs are prescribed to millions of people glo-
bally making a potential association with severity of COVID-19 
an issue of substantial public health importance. Population based 
epidemiological studies may help to address this issue. How-
ever, subtle differences in the characteristics of people prescribed 
ACEI and ARB, those prescribed ACEI or ARB for different 
indications and people prescribed ACEI or ARB compared to 
other antihypertensives can lead to non-causal associations in 
studies of drug effects. Recommendations about cessation or use 
of these important and evidence-based medications in relation to 
COVID-19 infection of these drugs may require completion of 
randomised clinical trials which are currently underway14,28.
Conclusion
Using primary care data in the UK, rates of infection with 
S. aureus are higher among users of ACEI compared to ARBs. 
However, other control outcomes also show an association with 
drug class, with similar or greater effect size. This suggests 
that there are sources of residual confounding in comparisons 
between users of ACEI and ARBs. Observational analyses study-
ing potential causal associations of outcomes with ACEI or ARB 
drugs, such as in relation to COVID-19 infection, should be 
conducted and interpreted with caution.
Data availability
Underlying data
The datasets used for these analyses are not publicly available 
due to Clinical Practice Research Datalink (CPRD) licensing 
restrictions. Data access through CPRD is subject to proto-
col approval by an Independent Scientific Advisory Committee 
(ISAC). All protocols must be submitted to the ISAC Secretariat 
using the Protocol Application Form. The protocol application 
form and where to submit the form are detailed on the CPRD 
website: https://cprd.com/research-applications.
LSHTM Data Compass: Codelist for: “Comparisons of Staphy-
lococcus aureus infection and other outcomes between users 
of angiotensin-converting-enzyme inhibitors and angiotensin 
II receptor blockers: lessons for COVID-19 from a nationwide 
cohort study”, https://doi.org/10.17037/data.0000166820
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
Extended data
LSHTM Research Online: Supplementary data for “Compari-
sons of Staphylococcus aureus infection and other outcomes 
between users of angiotensin-converting-enzyme inhibitors and 
angiotensin II receptor blockers: lessons for COVID-19 from 
a nationwide cohort study”, https://doi.org/10.17037/
PUBS.0465657819
This project contains the following extended data: 
- Supplementary Figure 1. Diagram of study design with 
definition of exposure periods.
- Supplementary Table 1. Characteristics of the 487,165 
study participants during follow-up.
- Supplementary Table 2. Crude rates and adjusted 
hazard ratio for the incidence of Staphylococcus aureus 
infections comparing periods prescribed angiotensin-
converting-enzyme inhibitors and angiotensin II 
receptor blockers.
- Supplementary Table 3. Crude rates and adjusted 
hazard ratio for the incidence of Staphylococcus aureus 
infection, comparing periods prescribed angiotensin-
converting-enzyme inhibitors and angiotensin II 
receptor blockers, stratified by calendar period and 
smoking status.
Data are available under the terms of the Creative Commons 
Attribution 3.0 International license (CC-BY 3.0).
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This is a well written article and robust study examining the association between ACEI use and the risk of
Staph aureus infections compared with exposure to ARBs. The study uses a large cohort of patients
identified from a well-established data source used for research. Such large data sources allow relatively
small associations to be identified that are statistically significant and these may raise public health
concern. For this reason, evaluating causality is very important.
 
Despite the underlying biological mechanism seen in animal studies the results of this study suggest that
the statistically significant association observed between ACEI use and Staph aureus infections is likely to
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 the statistically significant association observed between ACEI use and Staph aureus infections is likely to
be non-causal. This is supported by the finding of significant associations with several negative controls.
 
It is interesting to observe the stronger associations during unexposed periods of ACEI and ARB therapy
i.e. when withheld or withdrawn. I agree with the interpretation of the authors that this is likely to be in
keeping with patients being sicker or frailer during these spells. There could also be a contributing role of
prolonged periods of hospitalisation when routine prescriptions issued by the GP may not occur.
 
We are not completely sure therefore why this association is observed. Whilst unobserved confounders
may exist, significant associations remained robust despite adjustment with several addiitonal clinical
covariates. Whilst similar proportions of new ACE and new ARB users ultimately switch, far more patients
are new users of ACEI rather than new users of ARBs. Therefore much more person time exposed to an
ARB may result from having switched rather than being a new user of ARB. It is uncertain what proportion
of ARB person time results from being a new user as opposed to a switcher, and whether this type of
difference might be one source of the residual unmeasured confounding.
 
The supplementary material is very informative. As it is not too extensive it could be useful to deposit
this together with the main article so that everything is located in one place.
Overall, this study is a useful example of why it is important to test the robustness of significant
associations in observational studies before making recommendations to change clinical practice.
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